Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

JMP Securities Initiates Coverage On AN2 Therapeutics with Market Outperform Rating, Announces Price Target of $30

Author: Benzinga Newsdesk | January 04, 2024 06:03am
JMP Securities analyst Roy Buchanan initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform rating and announces Price Target of $30.

Posted In: ANTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist